Lataa...
Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
Relapsed urothelial cancer represents an unmet medical need. Vinflunine is a third-generation antimicrotubuline inhibitor and is currently the only approved drug for second-line treatment across the European Union. We conducted a retrospective analysis assessing the efficacy and safety of vinflunine...
Tallennettuna:
| Julkaisussa: | Anticancer Drugs |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Lippincott Williams & Wilkins
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4885529/ https://ncbi.nlm.nih.gov/pubmed/26421462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000297 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|